Discover an informative webinar that delves into the successes and failures of using real-world data and evidence in regulatory approvals.
The business of drug development and commercialization is undergoing a transformative shift, driven by the growing acceptance of real-world data/evidence in regulatory and reimbursement decision-making, coupled with unprecedented advancements in data analytics technologies.
In this webinar, the speakers will explore the profound implications of this convergence for pharmaceutical manufacturers and offer actionable insights into how to leverage these trends to optimize product development, reduce costs and maximize market access. The attendees will also get to discover how organizations can harness these powerful tools to drive innovation and improve clinical care.
They will share key lessons, including strategies to mitigate risks and ensure the robustness and reliability of real-world data and evidence. Moreover, they will examine how real-world data and evidence can streamline the drug development process — from drug discovery through to accelerating clinical trial timelines and informing critical go/no-go decisions.
The attendees will also learn how to leverage real-world data and evidence to optimize patient recruitment, refine study designs and validate clinical hypotheses. The speakers will also demonstrate how real-world data and evidence can support negotiations by showcasing real-world effectiveness and value and help develop compelling value propositions for payers and health technology assessment (HTA) bodies.
They will also address challenges associated with real-world data and evidence such as data privacy concerns, methodological limitations and integration issues, as well as share best practices for data collection, analysis and interpretation. Finally, they will explore how advanced analytics, including machine learning and artificial intelligence, are enhancing real-world data and evidence analysis to drive product development decisions.